Cerenome Advances CNS Oncology Platform and Trials
Houston, Texas, August 14, 2026 Cerenome, Inc. reported continued progress across its integrated central nervous system (CNS) oncology platform,...
radiotherapy
Advertisement
Avenda Health Expands Unfold AI Across Prostate Cancer Care
CULVER CITY, Calif., July 28, 2026 Avenda Health announced that its FDA-cleared Unfold AI platform is now being used...
Immutep Announces ESMO 2026 Presentation for EFTISARC-NEO Trial
SYDNEY, Australia – July 24, 2026 Immutep Limited has announced that an abstract from its investigator-initiated Phase II EFTISARC-NEO...
Laminar Completes CLINGLIO Trial Enrollment for LAM561
MALLORCA, Spain, July 23, 2026 Laminar Pharmaceuticals S.A. has announced the successful completion of patient recruitment for the CLINGLIO...
Alpha Tau Medical Ltd. Reports Positive Head and Neck Cancer Results
JERUSALEM, July 21, 2026 Alpha Tau Medical Ltd. announced positive clinical study results evaluating its Alpha DaRT® (Diffusing Alpha-emitters...
Advertisements
Alpha Tau Medical Ltd. Showcases Alpha DaRT Data
JERUSALEM, Israel – May 5, 2026 Alpha Tau Medical Ltd. has announced that new clinical data evaluating Alpha DaRT®...
Nanobiotix Updates Phase 3 NANORAY-312 Protocol
PARIS, France and CAMBRIDGE, Mass., United States – May 4, 2026 Nanobiotix has announced FDA acceptance of a protocol...
Nanobiotix to Present at Major U.S. Healthcare Events
Nanobiotix S.A. (Euronext: NANO, NASDAQ: NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches for cancer and other serious...
Advertisement
